ArticleRheumatology and therapy2022

Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.